Barry and Richard write on FCPA Compliance and Ethics Blog about the thinly veiled warning recently issued by the Director of the Serious Fraud Office, Richard Alderman to the pharmaceutical sector.

It has been well publicised that the pharmaceutical sector has been under increasing scrutiny from US regulators. Mr. Alderman spoke at a UK pharmaceutical conference about the industry, the Bribery Act and the SFO’s close co-operation with the US Department of Justice which is involved in a Foreign Corrupt Practices Act investigation into the pharmaceutical sector in the US.